Review
Recent insights into platinum drug resistance in cancer

https://doi.org/10.1016/S1368-7646(98)80005-8Get rights and content

Abstract

Cisplatin and its analogs have become important components of chemotherapeutic regimens for the treatment of solid tumors, however, their overall effectiveness is limited by the emergence of drug-resistant tumor cells. Resistance to the platinum drugs is multifactorial consisting of mechanisms that prevent the formation of lethal platinum-DNA adducts and mechanisms that operate downstream of the drug/target interaction to promote cell survival. Continued progress in the study of the drug resistance phenotype as well as the development of new platinum analogs may eventually lead to improved therapies and increased survival rates.

References (144)

  • HoskingLK et al.

    An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines

    Biochem Pharmacol

    (1990)
  • BrittenRA et al.

    The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells

    Biochem Pharmacol

    (1991)
  • HamiltonTC et al.

    Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion

    Biochem Pharmacol

    (1985)
  • DedonPC et al.

    Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles

    Biochem Pharmacol

    (1987)
  • IshikawaT et al.

    Glutathione-associated cisdiamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells

    J Biol Chem

    (1993)
  • EastmanA

    Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes

    Chem Biol Interact

    (1987)
  • MiyazakiM et al.

    Drug resistance to cisdiamminedichloroplatinum (II) in Chinese hamster ovary cell lines by transfection with glutathione S-transferase gene

    Biochem Biophys Res Comm

    (1990)
  • NakagawaK et al.

    Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines

    J Biol Chem

    (1990)
  • HrubiskoM et al.

    The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents

    Biochem Pharmacol

    (1993)
  • PattanaikA et al.

    Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein

    J Biol Chem

    (1992)
  • KojimaM et al.

    Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo

    Eur J Cancer

    (1994)
  • LindahlT et al.

    DNA excision repair pathways

    Curr Opin Genet & Dev

    (1997)
  • WoodRD

    Nucleotide Excision Repair in Mammalian Cells

    J Biol Chem

    (1997)
  • MoggsJG et al.

    Analysis of Incision Sites Produced by Human Cell Extracts and Purified Proteins during Nucleotide Excision Repair of a 1,3-Intrastrand d(GpTpG)-Cisplatin Adduct

    J Biol Chem

    (1996)
  • ThompsonLH

    Evidence that mammalian cells possess homologous recombinational repair pathways

    Mutat Res

    (1996)
  • LehmannAR

    Nucleotide excision repair and the link with transcription

    Trends Biochem Sci

    (1995)
  • YenL et al.

    Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents

    Mutat. Res

    (1995)
  • HughesEN et al.

    Purification of Nuclear Proteins That Bind to Cisplatin-damaged DNA

    J Biol Chem

    (1992)
  • McA'NultyM et al.

    The HMG-domain protein Ixrl blocks excision repair of cisplatin-DNA adducts in yeast

    Mutat Res

    (1996)
  • O'DwyerPJ et al.

    Cisplatin and its analogues

  • RobertsJJ et al.

    The mechanism of action of antitumor platinum compounds Prog

    Nucleic Acids Res

    (1979)
  • SheaTC et al.

    A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support

    J Clin Oncol

    (1989)
  • AlbertsDS et al.

    Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

    J Clin Oncol

    (1992)
  • SchilderRJ et al.

    Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule

    Cancer Res

    (1994)
  • HarstrickA et al.

    Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines

    Cancer Chemother. Pharmacol

    (1993)
  • GietemaJA et al.

    Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

    Br J Cancer

    (1995)
  • DegardinM et al.

    A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer

    Invest New Drugs

    (1995)
  • KhokharAR et al.

    Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum (IV) carboxylate complexes

    J. Med Chem

    (1997)
  • HarrapKR

    Initiatives with platinum- and quinazoline-based antitumor molecules — Fourteenth Bruce F. Cain memorial award lecture

    Cancer Res

    (1995)
  • HolfordJ et al.

    In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

    Br J Cancer

    (1998)
  • FarrellN

    Structurally novel platinum antitumor compounds

  • ZaludovaR et al.

    DNA interactions of bifunctional dinuclear platinum (II) antitumor agents

    Eur J Biochem

    (1997)
  • PlooyACM et al.

    The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques

    Carcinogenesis

    (1985)
  • Fichtinger-SchepmanAM et al.

    Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification and quantitation

    Biochemistry

    (1985)
  • BlommaertFA et al.

    Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells

    Biochemistry

    (1995)
  • ShermanSE et al.

    Structural aspects of platinum anticancer drug interactions with DNA

    Chem Rev

    (1987)
  • SzymkowskiDE et al.

    An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts

  • KnoxRJ et al.

    Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA

    Cancer Res

    (1986)
  • SarisCP et al.

    In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured cells

    Carcinogenesis

    (1996)
  • EastmanA

    Mechanisms of resistance to cisplatin

    Cancer Treat Res

    (1991)
  • Cited by (0)

    View full text